8-K: Hyperfine, Inc. Faces Nasdaq Delisting Threat Due to Low Stock Price

Hyperfine, Inc. received a notice from Nasdaq for failing to meet the minimum bid price requirement, putting its listing at risk.

Summary

• Hyperfine, Inc. received a notice from Nasdaq on April 30, 2025, stating that its Class A common stock has fallen below $1.00 per share for 30 consecutive business days.
• This violates Nasdaq Listing Rule 5450(a)(1), which requires a minimum bid price of $1.00 per share for continued listing on The Nasdaq Global Market.
• The notice does not immediately affect the listing or trading of Hyperfine's common stock, which continues to trade on Nasdaq under the symbol HYPR.
• Hyperfine has an initial period of 180 calendar days, until October 27, 2025, to regain compliance by having its stock price close at or above $1.00 per share for at least 10 consecutive business days.
• If Hyperfine fails to regain compliance by the Compliance Date, it may be eligible for an additional 180-day compliance period by transferring its listing to The Nasdaq Capital Market and meeting other listing requirements.
• This transfer would require paying an application fee and providing written notice of the company's intention to cure the deficiency.
• If Hyperfine fails to cure the deficiency within the additional compliance period, Nasdaq may issue a delisting notification, which the company can appeal to a Nasdaq Hearings Panel.
• There is no guarantee that an appeal would be successful.
• Hyperfine intends to monitor its stock price and consider all available options to regain compliance, but there is no assurance it will be successful or receive an extension.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice, indicating financial distress and potential challenges for the company's future.

Positives

• The notice has no immediate effect on the listing or trading of Hyperfine's common stock.
• Hyperfine has been granted an initial 180-day period to regain compliance.
• The company may be eligible for an additional 180-day compliance period if it transfers to The Nasdaq Capital Market.

Negatives

• Hyperfine's stock price has fallen below the minimum bid price requirement for continued listing on The Nasdaq Global Market.
• There is no assurance that Hyperfine will be able to regain compliance with the Bid Price Requirement.
• Delisting from Nasdaq could negatively impact investor confidence and the company's ability to raise capital.

Risks

• Failure to regain compliance with Nasdaq listing rules could result in delisting.
• Delisting could negatively impact the company's stock price and investor confidence.
• There is no guarantee that the company will be granted an extension to regain compliance.
• The company may need to implement a reverse stock split to increase its stock price, which could dilute existing shareholders' ownership.

Future Outlook

Hyperfine intends to monitor the closing bid price of its Common Stock and will consider all available options to regain compliance with the Bid Price Requirement. However, there can be no assurance that the Company will be able to regain compliance with the Bid Price Requirement or that the Staff will grant the Company a further extension of time to regain compliance, if applicable.

Management Comments

• Hyperfine intends to monitor the closing bid price of its Common Stock and will consider all available options to regain compliance with the Bid Price Requirement.

Industry Context

Companies in the medical device industry, especially those that are still in a growth phase, can face challenges in maintaining stock prices, particularly if they are not yet profitable or if market sentiment shifts. Delisting notices are not uncommon for companies in this sector.

Comparison to Industry Standards

• Many small-cap and micro-cap companies in the medical device sector face similar challenges with maintaining Nasdaq listing requirements.
• Comparable companies that have faced similar situations include those with limited revenue or those undergoing significant R&D investments.
• For example, companies like 'Zomedica' and 'TherapeuticsMD' have previously navigated similar compliance issues with Nasdaq's minimum bid price rule.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment.
• Employees may face uncertainty regarding the company's future.
• The company's ability to raise capital may be negatively impacted.

Next Steps

• Hyperfine will monitor its stock price.
• Hyperfine will consider all available options to regain compliance with the Bid Price Requirement.
• Hyperfine may transfer the listing of its Common Stock to The Nasdaq Capital Market.
• Hyperfine may implement a reverse stock split.

Key Dates

Keywords

delisting, Nasdaq, compliance, stock price, HYPR, Hyperfine, minimum bid price